HealthEconomics.Com’s Pharma Pricing and Reimbursement Stories in This Week’s Newsletter

If we are transparent on how drugs are priced, does it lower costs? What is per patient cost of Specialty Pharmaceuticals?

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

HealthEconomics.com

Ponte Vedra Beach, Florida (PRWEB) April 01, 2013

The top read story this week on HealthEconomics.Com was from a Healthy Criticism Blog posting by Nick Emptage, exploring why price transparency in pharmaceuticals and healthcare won’t reduce healthcare spending. Economist Emptage reflected on the business model of San Francisco-based Castlight Health, a company which contracts with employers to make the costs of health services transparent to employees. The idea is that employees will then lean toward lower-cost providers. Nick's blog points out the flaws of this idea as it relates to the health care market.

Another story of interest relates to comments by Jon Sussex, a member of the United Kingdom-based Office of Health Economics (OHE) Commission on Competition in the National Health Service (NHS). Sussex reflects on the revised draft of regulations to govern competition among providers of health care funded by the NHS in England; the first draft was replaced due to wide criticism. The article includes comments relating to the required use of competition by NHS in obtaining health care services for their populations unless there are good reasons not to do so.

The third most popular story on HealthEconomics.Com explored whether US taxpayers enjoy lower drug prices if federal money backed development. This question was based on actions by Senator Ron Wyden (Oregon-D), who has delved into this issue to explore the return-on-investment to the public based on tax dollar use for drug development. Should some of that return come in the form of lower prices on drugs developed with federal support? Original article sourced from FiercePharma.

About HealthEconomics.Com (http://www.healtheconomics.com):
A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn

Attachments